Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.36 |
| ▸ | FEN1 | P39748 | 4/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2006811 | 0.84 | PTPRC (0.43) | PTPRCNMUR2S100A4ALOX5APFEN1 | |
| SCHEMBL1711745 | 0.83 | FABP4 (0.42) | ALOX5APFEN1TDP1ALDH1A1HSD17B10 | |
| SCHEMBL6291104 | 0.81 | ALDH1A1 (0.43) | PTPRCAKR1B1KAT6ATDP1ALDH1A1 | |
| SCHEMBL29467282 | 0.77 | AKR1B1 (0.49) | S100A4AKR1B1ALDH1A1DGAT1 | |
| SCHEMBL121016 | 0.77 | AKR1B1 (0.49) | S100A4AKR1B1ALDH1A1DGAT1 | |
| SCHEMBL2010580 | 0.77 | MMP1 (0.47) | PTPRCNMUR2S100A4ALOX5APFEN1 | |
| SCHEMBL11728016 | 0.77 | PTPRC (0.47) | PTPRCNMUR2S100A4ALOX5APFEN1 | |
| SCHEMBL197054 | 0.77 | S100A4 (0.48) | PTPRCS100A4 | |
| SCHEMBL7127239 | 0.76 | ALDH1A1 (0.48) | PTPRCS100A4TDP1MAPK1ALDH1A1 | |
| SCHEMBL12570991 | 0.75 | MMP1 (0.52) | S100A4ALOX5APFEN1AKR1B1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137141-B1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | UNIV ABERDEEN (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2137141-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | The University Court of The University of Aberdeen (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008114022-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-25 | — | — | WO | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | ARSA, SOST, AHR | PTPRC 619/4885NMUR2 4256/4885CHRM5 4093/4885 |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | PTPRC 2028/4885NMUR2 4803/4885CHRM5 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.